drugset / Trial / NCT03935555
Assess the Safety, Tolerability Oral PU-H71 in Subjects Taking Ruxolitinib
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a multicenter, Phase 1b study with dose escalation and expansion cohorts designed to assess the safety, tolerability, PK, and preliminary efficacy of PU-H71 in subjects with PMF, Post-PV MF, Post-ET MF, taking stable doses of ruxolitinib.
Timeline
- Start
- 2019-08-12
- Primary completion
- 2022-10-19
- Completion
- 2022-11-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PU-H71 | Small molecule | 50 mg | Oral |
| Subject | PU-H71 | Small molecule | 100 mg | Oral |
| Subject | PU-H71 | Small molecule | 200 mg | Oral |
| Subject | PU-H71 | Small molecule | 300 mg | Oral |